COVID-19: AstraZeneca CEO on long-term safety from jab

The boss of pharmaceutical large AstraZeneca says its coronavirus vaccine – developed with Oxford University – could have performed a key position in decreasing Covid-related hospitalisations within the UK.

Pascal Soriot mentioned his firm’s vaccine promoted a better T-cell [part of the immune system which defends the body against specific infections] response in older folks than some others.

Mr Soriot was chatting with the Today programme forward of the formal opening of AstraZeneca’s new science lab in Cambridge.


Leave a Reply

Your email address will not be published.

Back to top button

Adblocker detected! Please consider reading this notice.

We've detected that you are using AdBlock Plus or some other adblocking software which is preventing the page from fully loading. We don't have any banner, Flash, animation, obnoxious sound, or popup ad. We do not implement these annoying types of ads! We need money to operate the site, and almost all of it comes from our online advertising. Please add to your ad blocking whitelist or disable your adblocking software.